Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-11

Study Completion Date

2019-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial aims to determine whether the early bactericidal activity of rifampicin given with faropenem or cefadroxil (each given with amoxicillin/clavulanic acid) is greater than the activity of rifampicin alone in patients with pulmonary TB. The trial will also investigate potential new biomarkers of sterilising activity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

NCT02393586

Tuberculosis

COMPLETED PHASE1

Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB

NCT03174184

Tuberculosis, Pulmonary

COMPLETED PHASE2

Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients

NCT02169141

Tuberculosis

COMPLETED

Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin

NCT02975570

Tuberculosis Multi Drug Resistant Active

WITHDRAWN PHASE3

Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients

NCT01055145

TB

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberculosis (TB) remains one of the leading causes of mortality from an infectious disease worldwide with approximately 2 million deaths annually. There is an urgent need to identify new drugs, especially drugs with activity against persistent organisms that may enable shorter treatment regimens. Beta-lactam antibiotics have activity against TB in vitro and in animal models and there is evidence of synergy with rifampicin, one of the standard TB drugs. Amongst oral beta-lactam antibiotics, two appear to have optimal properties and optimal synergy with rifampicin and may be candidates for adjunctive treatment of drug-sensitive TB: faropenem (an oral penem, closely related to the carbapenem class) and cefadroxil (a first generation cephalosporin). Both drugs are used widely for the treatment of bacterial infections. They have in vitro activity against Mycobacterium tuberculosis, which is augmented when administered with rifampicin.

This is a Phase II randomised, controlled, open-label, early bactericidal activity trial. We will recruit patients between the ages of 18 and 70 with newly-diagnosed smear positive pulmonary TB, who have not yet started TB therapy.

Patients will be randomised into one of 3 arms to take faropenem (with amoxicillin/clavulanic acid) plus rifampicin, or cefadroxil (with amoxicillin/ clavulanic acid) plus rifampicin, or rifampicin alone for the first two days of the study. Patients will start standard TB therapy on the third day of the study and continue with the beta lactam antibiotics for the remaining 5 days of the study. Following the completion of the 7 days of study medication, the study will end and patients will continue standard combination TB therapy under normal clinical follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Faropenem

Faropenem 600mg (with amoxicillin/clavulanic acid, 500mg/125mg) given three times daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days

Group Type EXPERIMENTAL

Faropenem

Intervention Type DRUG

Faropenem 600mg

Amoxicillin/clavulanic acid

Intervention Type DRUG

Amoxicillin 500mg/ clavulanic acid 125mg

Cefadroxil

Cefadroxil 1g (with amoxicillin/clavulanic acid, 500mg/125mg) given twice daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days

Group Type EXPERIMENTAL

Amoxicillin/clavulanic acid

Intervention Type DRUG

Amoxicillin 500mg/ clavulanic acid 125mg

Cefadroxil

Intervention Type DRUG

Cefadroxil 1g

Control

Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days

Group Type ACTIVE_COMPARATOR

Rifampicin

Intervention Type DRUG

Rifampicin 10mg/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Faropenem

Faropenem 600mg

Intervention Type DRUG

Amoxicillin/clavulanic acid

Amoxicillin 500mg/ clavulanic acid 125mg

Intervention Type DRUG

Cefadroxil

Cefadroxil 1g

Intervention Type DRUG

Rifampicin

Rifampicin 10mg/kg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Farobact 200 Augmentin Co-amoxiclav Rifampin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged 18 to 70 years
2. Clinical features compatible with pulmonary TB
3. Sputum smear graded at least 1 +
4. Estimated to be producing at least 5ml of sputum per day
5. Willing to comply with study procedures and able to provide written informed consent.

Exclusion Criteria

1. Suspected miliary TB or TB meningitis
2. Patients receiving any TB treatment within the previous 6 months
3. Patients too ill to tolerate a 2-3 day delay in standard therapy
4. Concurrent bacterial pneumonia
5. Known hypersensitivity to beta-lactam drugs (penicillins, carbapenems) or rifampicin
6. History of severe allergies or severe asthma
7. Receiving loop diuretics
8. Estimated creatinine clearance \< 80 ml/min on screening blood test
9. ALT \> 2.5 times upper limit of normal on screening blood test.
10. Presence of rifampicin resistance on GeneXpert (or alternative molecular test).
11. Women who are currently pregnant or breastfeeding.
12. Any other significant condition that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial.
13. Participation in other clinical intervention trial or research protocol

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No